Investor Presentaiton
Life Sciences Overview
~$7.0B
TOTAL REVENUE
2022
Revenue
By Mix
Non-
recurring
Recurring
BECKMAN
COULTER
PALL
SCIEX
Life Sciences
Industrial
aldevron phenomenex®
GLOBAL GROWTH DRIVERS
Leica XIDT
MICROSYSTEMS
INTEGRATED DNA TECHNOLOGIES
MOLECULAR
DEVICES
IDBS
By Geography
HGM
ROW
NA
W. EU
All financial metrics reflect FY 2022 results from
continuing operations; all pie chart percentages are
% of 2022 revenues.
.
Shift in medicine towards biologics
By End-Market
.
Increasing focus on genomic medicine
Clinical
Biopharma
Rsrch./ & Pharma
Acad.
Ind. Applied
Adoption of gene editing and sequencing technologies
Global investments in basic & applied research capacity
Strong global brands with leading market positions
19
DANAHERView entire presentation